Perceptive Advisors LLC lifted its holdings in Agile Therapeutics Inc (NASDAQ:AGRX) by 11.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,919,925 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,193,175 shares during the period. Perceptive Advisors LLC owned about 0.20% of Agile Therapeutics worth $29,799,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jane Street Group LLC bought a new position in Agile Therapeutics in the fourth quarter worth approximately $28,000. Schonfeld Strategic Advisors LLC bought a new stake in Agile Therapeutics during the fourth quarter valued at about $2,224,000. Bank of New York Mellon Corp boosted its position in Agile Therapeutics by 74.6% during the fourth quarter. Bank of New York Mellon Corp now owns 53,834 shares of the specialty pharmaceutical company’s stock valued at $135,000 after purchasing an additional 23,005 shares in the last quarter. Oxford Asset Management LLP bought a new stake in Agile Therapeutics during the fourth quarter valued at about $170,000. Finally, Renaissance Technologies LLC grew its stake in Agile Therapeutics by 34.5% in the fourth quarter. Renaissance Technologies LLC now owns 3,265,601 shares of the specialty pharmaceutical company’s stock valued at $8,164,000 after purchasing an additional 838,501 shares during the last quarter. 39.27% of the stock is owned by hedge funds and other institutional investors.

In other news, CEO Alfred Altomari acquired 10,000 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were acquired at an average price of $2.71 per share, with a total value of $27,100.00. Following the purchase, the chief executive officer now directly owns 301,611 shares of the company’s stock, valued at $817,365.81. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive acquired 3,000,000 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were purchased at an average cost of $3.02 per share, for a total transaction of $9,060,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 4,060,000 shares of company stock worth $10,953,100. 8.50% of the stock is owned by corporate insiders.

AGRX has been the topic of a number of recent analyst reports. HC Wainwright lowered their price target on shares of Agile Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, March 20th. Zacks Investment Research cut shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. ValuEngine raised shares of Agile Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, March 13th. Janney Montgomery Scott increased their price objective on Agile Therapeutics from $4.00 to $9.00 and gave the company a “fair value” rating in a report on Wednesday, February 19th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $8.00 target price on shares of Agile Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $5.83.

Shares of AGRX traded up $0.08 during trading hours on Thursday, reaching $2.01. 2,033,541 shares of the company traded hands, compared to its average volume of 4,111,515. The stock has a market capitalization of $134.73 million, a P/E ratio of -5.15 and a beta of 1.09. Agile Therapeutics Inc has a 12-month low of $0.35 and a 12-month high of $4.77. The business has a fifty day moving average price of $2.85 and a 200-day moving average price of $2.19.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Thursday, February 20th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.02). On average, analysts anticipate that Agile Therapeutics Inc will post -0.52 EPS for the current fiscal year.

Agile Therapeutics Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

See Also: How the Consumer Price Index (CPI) is calculated?

Want to see what other hedge funds are holding AGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agile Therapeutics Inc (NASDAQ:AGRX).

Institutional Ownership by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.